Brenton Mar

Translating genomics into new therapies in cancer patients. Views are my own.

[Relay Therapeutics @Relay_Tx]

Today, we announced a clinical trial collaboration to develop RLY-2608 with atirmociclib, Pfizer’s next-generation selective CDK4 inhibitor currently in Phase 1 studies, in triplet combination in patients with PI3Kα-mutated, HR+, HER2-metastatic #breastcancer. Clinical start by YE 2024. Find full details here. https://t.co/xawTM13Wlj $RLAY

[Scott Gottlieb, MD 🇺🇸 @ScottGottliebMD]

Cancers should no longer be classified only by their organ of origin - it's time for molecular characteristics to be used to classify tumors; for clinical practice as well as regulatory decision making.

Commentary @Nature h/t @EricTopol

[Neil Vasan @NeilVasan]

Thrilled to announce the launch of our new patient advocacy organization @PIK3CApathbreak ers! We are excited about partnering with pts, advocates, oncologists, biotech, pharma, and others to improve care for pts with PIK3CA altered breast cancer.

[Dr Sarah Sammons @drsarahsam]

I would say it’s a mute point since alpelisib use will decline significantly due to capivasertib.

I would be interested to hear more about the “programming error” and which program was used so that we can learn from it for future trials.

[Dr Sarah Sammons @drsarahsam]

50% of patients after progression on PIK3CA inhibitors acquire secondary genomic alterations within the PI3K-pathway.

All mutations overcome by novel patient allosteric PIK3CA inhibitor RLY2608.

Great work ⁦@AndreasVarkaris⁩! https://t.co/D0I3APQgRT

[Relay Therapeutics @Relay_Tx]

Our first publication on RLY-2608, an investigational, first known isoform and mutant-selective allosteric PI3Kα inhibitor, is officially live in @CD_AACR. We extend our most sincere gratitude to our remarkable team of Relayers, collaborators, investigators and patients who are driving this program forward. https://t.co/mZOSupCSu5

[Brenton Mar @BrentonMar]

https://t.co/TMXLUJeoPV

[Brenton Mar @BrentonMar]

@ASH_hematology @AbdelWahablab @theNCI @DrAlexisThompsn @ChildrensPhila @MSKCancerCenter @MDAndersonNews @lab_rezvani @OMRF @WeillCornell @DanaFarber Congrats Omar!

[Relay Therapeutics @Relay_Tx]

This exciting publication on RLY-4008 is officially live in
@AACR Cancer Discovery Journal. Special thanks to our incredible team of Relayers, Vivek Subbiah of @MDAndersonNews & our collaborators and investigators for their relentless dedication to the advancement of this investigational medicine. We look forward to the continued progression of RLY-4008 for patients across the world. https://t.co/7LkKsmZqGn

[Brenton Mar @BrentonMar]

@geoff_oxnard @pashtoonkasi @VivekSubbiah @Relay_Tx Yes! @pashtoonkasi told me himself at the your FGFR2 poster! You know I’m a big fan of ctDNA. Sensitivity is irrelevant if you can’t get a sample.

[Bio Stocks™ @BioStocks]

$BPMC FDA Approves AYVAKIT as the First and Only Treatment for Indolent Systemic Mastocytosis

https://t.co/BJFJoBSMjd

[Jennifer A. Marks, MD @jennifermarksmd]

PACC EGFR mt is a heterogenous population in NSCLC. Structure and function classification guides tx selections and development. #TTLC23 @LeXiuning #LCSM @IASLC

[Ivy Elkins @ivybelkins]

Lots of hope for those with #C797S resistance mechanisms to #osimertinib. Look at all these compounds in development! @JuliaRotow @EGFRResisters #lcsm #EGFR #lungcancer #TTLC23

[Ivy Elkins @ivybelkins]

Unanswered questions and future directions in #EGFR #Exon20insertions #lcsm #EGFR #lungcancer @ZPiotrowskaMD #TTLC23 @EGFRResisters @Exon20Group

[Fawzi Abu Rous, MD @FawziAbuRous]

@JSabari at #TTLC23: if you don’t test for #METex14 you won’t find it!

Don’t skip #METex14 skipping mutation!
@IASLC #lcsm

[Xiuning Le MD PhD @LeXiuning]

Honored to discuss "rare EGFR mutations" at #TTLC23 with friends and colleagues. @EGFRResisters @Exon20Group. Trials are ongoing for PACC mutations!

[Web Chronicle Today @WebChronicleTo1]

$BPMC Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints

https://t.co/c1nujT5g9v

[Brenton Mar @BrentonMar]

@adamssperling @anguyen4194 @BrighamHeme Congrats Adam!

[Brenton Mar @BrentonMar]

My dad was just diagnosed in April with stage 4 Lung Cancer. May is Lung Cancer Hope month. Please help give patients hope by supporting research and support at LUNGevity:
https://t.co/SfKcfjoQpV

[Brenton Mar @BrentonMar]

@DavidSteensma Hey Dave! Just landed in NOLA—any time for a coffee to catch up?